During the past decade, Clinical Research Center of Reading,LLC conducted 28 clinical trials. In the 10-year time frame, 28 clinical trials started and 50 clinical trials were completed, i.e. on average, 178.6% percent of trials that started reached the finish line to date. In the past 5 years, 8 clinical trials started and 22 clinical trials were completed. i.e. 275% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Clinical Research Center of Reading,LLC" #1 sponsor was "Pfizer" with 15 trials, followed by "Eli Lilly and Company" with 13 trials sponsored, "Hoffmann-La Roche" with 7 trials sponsored, "Bristol-Myers Squibb" with 4 trials sponsored and "Cephalon" with 4 trials sponsored. Other sponsors include 27 different institutions and companies that sponsored additional 25 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Clinical Research Center of Reading,LLC" #1 collaborator was "Incyte Corporation" with 3 trials as a collaborator, "Ono Pharmaceutical Co. Ltd" with 2 trials as a collaborator, "Astellas Pharma US, Inc." with 1 trials as a collaborator, "Biogen" with 1 trials as a collaborator and "Galapagos NV" with 1 trials as a collaborator. Other collaborators include 0 different institutions and companies that were collaborators in the rest 10 trials.

According to Clinical.Site data, the most researched conditions in "Clinical Research Center of Reading,LLC" are "Rheumatoid Arthritis" (27 trials), "Osteoarthritis" (8 trials), "Arthritis, Rheumatoid" (7 trials), "Chronic Pain" (4 trials) and "Lupus Erythematosus, Systemic" (4 trials). Many other conditions were trialed in "Clinical Research Center of Reading,LLC" in a lesser frequency.

Most popular intervention types in "Clinical Research Center of Reading,LLC" are "Drug" (63 trials), "Biological" (10 trials), "Other" (7 trials) and "Device" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (31 trials), "Baricitinib" (6 trials), "Methotrexate" (6 trials), "Tocilizumab" (4 trials) and "Abatacept" (3 trials). Other intervention names were less common.

The vast majority of trials in "Clinical Research Center of Reading,LLC" are 72 trials for "All" genders and 2 trials for "Female" genders.

Currently, there are NaN active trials in "Clinical Research Center of Reading,LLC". undefined are not yet recruiting, undefined are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 64 completed trials in Clinical Research Center of Reading,LLC, undefined suspended trials, and 7 terminated clinical trials to date.

Out of the total trials that were conducted in Clinical Research Center of Reading,LLC, 2 "Phase 1" clinical trials were conducted, 26 "Phase 2" clinical trials and 38 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 5 trials, and there were also 3 trials that are defined as “Not Applicable".